Strong development for MaxCyte

26 September 2020 - 16:33
MaxCyte has had a strong year so far and things are looking good according to Doug Doefler at MaxCyte. Their full-year revenues which are on track to be 'slightly above' current market expectations....
London AIM (United Kingdom)
Maxcyte provides patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology....
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date